Shots:

• Ovid to receive milestones payments upon achievement of clinical, regulatory & commercial milestones for gaboxadol’s development along with royalties on net sales based on marketed therapies containing gaboxadol
• The recent collaboration follows Healx’s Aug 2021 research collaboration agreement with Ono. Healx obtains exclusive license rights to develop & commercialize gaboxadol while Ovid gets an option to become Healx’s co-development & co-commercialization partner and will share net profits & losses
• Healx plans to explore gaboxadol in combination therapies for Fragile X syndrome & for other indications & plans to utilize its cutting-edge indication expansion technology to identify other conditions

Ref: Globe Newswire | Image: Businesswire